{"id":"acyclovir-sodium","_fda":{"id":"3a390591-86f7-b68d-e063-6294a90a8bcc","set_id":"23a7cf9e-f21b-06c2-e063-6394a90aa623","openfda":{"unii":["927L42J563"],"route":["INTRAVENOUS"],"rxcui":["1734934"],"spl_id":["3a390591-86f7-b68d-e063-6294a90a8bcc"],"brand_name":["Acyclovir Sodium"],"spl_set_id":["23a7cf9e-f21b-06c2-e063-6394a90aa623"],"package_ndc":["84549-155-20"],"product_ndc":["84549-155"],"generic_name":["ACYCLOVIR SODIUM"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["ACYCLOVIR SODIUM"],"manufacturer_name":["ProPharma Distribution"],"application_number":["ANDA203701"],"original_packager_product_ndc":["55150-155"]},"version":"3","warnings":["WARNINGS Acyclovir Sodium Injection is intended for intravenous infusion only, and should not be administered topically, intramuscularly, orally, subcutaneously, or in the eye. Intravenous infusions must be given over a period of at least 1 hour to reduce the risk of renal tubular damage (see PRECAUTIONS and DOSAGE AND ADMINISTRATION ). Renal failure, in some cases resulting in death, has been observed with acyclovir therapy (see ADVERSE REACTIONS, Observed During Clinical Practice and OVERDOSAGE ). Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), which has resulted in death, has occurred in immunocompromised patients receiving acyclovir therapy."],"pregnancy":["Pregnancy Teratogenic Effects Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg/day, PO), rabbit (50 mg/kg/day, SC and IV), or rat (50 mg/kg/day, SC). These exposures resulted in plasma levels the same as, 4 and 9, and 1 and 2 times, respectively, human levels. There are no adequate and well-controlled studies in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus."],"overdosage":["OVERDOSAGE Overdoses involving ingestions of up to 20 g have been reported. Adverse events that have been reported in association with overdosage include agitation, coma, seizures, and lethargy. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Overdosage has been reported following bolus injections or inappropriately high doses, and in patients whose fluid and electrolyte balance were not properly monitored. This has resulted in elevated BUN and serum creatinine, and subsequent renal failure. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored (see DOSAGE AND ADMINISTRATION )."],"description":["DESCRIPTION Acyclovir Sodium Injection is a synthetic nucleoside analog, active against herpes viruses. It is a sterile, aqueous solution for intravenous infusion, containing 50 mg acyclovir per mL in Water for Injection, USP. The concentration is equivalent to 54.9 mg of acyclovir sodium per mL in Water for Injection, USP. The sodium content is approximately 5.1 mg/mL. The pH range of the solution is 10.85 to 11.50. Further dilution of Acyclovir Sodium Injection in an appropriate intravenous solution must be performed before infusion (see DOSAGE AND ADMINISTRATION, Administration ). The chemical name of acyclovir sodium is 9-[(2-Hydroxyethoxy)methyl] guanine, and has the following structural formula: Acyclovir USP is a white to off-white, crystalline powder. Acyclovir sodium is the sodium salt of acyclovir, which is formed in situ , with the molecular formula C 8 H 10 N 5 NaO 3 and a molecular weight of 247.19. The maximum solubility in water at 25°C exceeds 100 mg/mL. At physiologic pH, acyclovir sodium exists as the unionized form with a molecular weight of 225 and a maximum solubility in water at 37°C of 2.5 mg/mL. The pka’s of acyclovir are 2.27 and 9.25. Acyclovir Sodium Chemical Structure"],"precautions":["PRECAUTIONS General Precipitation of acyclovir crystals in renal tubules can occur if the maximum solubility of free acyclovir (2.5 mg/mL at 37°C in water) is exceeded or if the drug is administered by bolus injection. Ensuing renal tubular damage can produce acute renal failure. Abnormal renal function (decreased creatinine clearance) can occur as a result of acyclovir administration and depends on the state of the patient’s hydration, other treatments, and the rate of drug administration. Concomitant use of other nephrotoxic drugs, pre-existing renal disease, and dehydration make further renal impairment with acyclovir more likely. Administration of acyclovir by intravenous infusion must be accompanied by adequate hydration. When dosage adjustments are required, they should be based on estimated creatinine clearance (see DOSAGE AND ADMINISTRATION ). Approximately 1% of patients receiving intravenous acyclovir have manifested encephalopathic changes characterized by either lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma. Acyclovir should be used with caution in those patients who have underlying neurologic abnormalities and those with serious renal, hepatic, or electrolyte abnormalities, or significant hypoxia. Drug Interactions See CLINICAL PHARMACOLOGY, Pharmacokinetics . Carcinogenesis, Mutagenesis, Impairment of Fertility The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with 30 mg/kg/day (10 mg/kg every 8 hours, dosing appropriate for treatment of herpes zoster or herpes encephalitis), or 15 mg/kg/day (5 mg/kg every 8 hours, dosing appropriate for treatment of primary genital herpes or herpes simplex infections in immunocompromised patients). Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see CLINICAL PHARMACOLOGY, Pharmacokinetics ). Acyclovir was tested in lifetime bioassays in rats and mice at single daily doses of up to 450 mg/kg administered by gavage. There was no statistically significant difference in the incidence of tumors between treated and control animals, nor did acyclovir shorten the latency of tumors. At 450 mg/kg/day, plasma concentrations in both the mouse and rat bioassay were lower than concentrations in humans. Acyclovir was tested in 16 in vitro and in vivo genetic toxicity assays. Acyclovir was positive in 5 of the assays. Acyclovir did not impair fertility or reproduction in mice (450 mg/kg/day, PO) or in rats (25 mg/kg/day, SC). In the mouse study, plasma levels were the same as human levels, while in the rat study, they were 1 to 2 times human levels. At higher doses (50 mg/kg/day, SC) in rats and rabbits (1 to 2 and 1 to 3 times human levels, respectively) implantation efficacy, but not litter size, was decreased. In a rat peri- and post-natal study at 50 mg/kg/day, SC, there was a statistically significant decrease in group mean numbers of corpora lutea, total implantation sites, and live fetuses. No testicular abnormalities were seen in dogs given 50 mg/kg/day, IV for 1 month (1 to 3 times human levels) or in dogs given 60 mg/kg/day orally for 1 year (the same as human levels). Testicular atrophy and aspermatogenesis were observed in rats and dogs at higher dose levels. Pregnancy Teratogenic Effects Acyclovir administered during organogenesis was not teratogenic in the mouse (450 mg/kg/day, PO), rabbit (50 mg/kg/day, SC and IV), or rat (50 mg/kg/day, SC). These exposures resulted in plasma levels the same as, 4 and 9, and 1 and 2 times, respectively, human levels. There are no adequate and well-controlled studies in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of birth defects approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nursing Mothers Acyclovir concentrations have been documented in breast milk in two women following oral administration of acyclovir and ranged from 0.6 to 4.1 times corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg/day. Acyclovir should be administered to a nursing mother with caution and only when indicated. Pediatric Use See DOSAGE AND ADMINISTRATION . Geriatric Use Clinical studies of acyclovir did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. Other reported clinical experience has identified differences in the severity of CNS adverse events between elderly and younger patients (see ADVERSE REACTIONS, Observed During Clinical Practice ). In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased renal function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"how_supplied":["HOW SUPPLIED NDC 84549-155-20 - 1 Single Dose Vial, 20mL"],"geriatric_use":["Geriatric Use Clinical studies of acyclovir did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger patients. Other reported clinical experience has identified differences in the severity of CNS adverse events between elderly and younger patients (see ADVERSE REACTIONS, Observed During Clinical Practice ). In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased renal function, and of concomitant disease or other drug therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function."],"pediatric_use":["Pediatric Use See DOSAGE AND ADMINISTRATION ."],"effective_time":"20250718","nursing_mothers":["Nursing Mothers Acyclovir concentrations have been documented in breast milk in two women following oral administration of acyclovir and ranged from 0.6 to 4.1 times corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg/day. Acyclovir should be administered to a nursing mother with caution and only when indicated."],"adverse_reactions":["ADVERSE REACTIONS The adverse reactions listed below have been observed in controlled and uncontrolled clinical trials in approximately 700 patients who received acyclovir at approximately 5 mg/kg (250 mg/m 2 ) 3 times daily, and approximately 300 patients who received approximately 10 mg/kg (500 mg/m 2 ) 3 times daily. The most frequent adverse reactions reported during administration of acyclovir were inflammation or phlebitis at the injection site in approximately 9% of the patients, and transient elevations of serum creatinine or BUN in 5% to 10% (the higher incidence occurred usually following rapid [less than 10 minutes] intravenous infusion). Nausea and/or vomiting occurred in approximately 7% of the patients (the majority occurring in nonhospitalized patients who received 10 mg/kg). Itching, rash, or hives occurred in approximately 2% of patients. Elevation of transaminases occurred in 1% to 2% of patients. The following hematologic abnormalities occurred at a frequency of less than 1%: anemia, neutropenia, thrombocytopenia, thrombocytosis, leukocytosis, and neutrophilia. In addition, anorexia and hematuria were observed. Observed During Clinical Practice In addition to adverse events reported from clinical trials, the following events have been identified during post-approval use of Acyclovir Sodium Injection in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, potential causal connection to acyclovir, or a combination of these factors. General: Anaphylaxis, angioedema, fatigue, fever, headache, pain, peripheral edema. Digestive: Abdominal pain, diarrhea, gastrointestinal distress, nausea. Cardiovascular: Hypotension. Hematologic and Lymphatic: Disseminated intravascular coagulation, hemolysis, leukocytoclastic vasculitis, leukopenia, lymphadenopathy. Hepatobiliary Tract and Pancreas : Elevated liver function tests, hepatitis, hyperbilirubinemia, jaundice. Musculoskeletal: Myalgia. Nervous: Aggressive behavior, agitation, ataxia, coma, confusion, delirium, dizziness, dysarthria, encephalopathy, hallucinations, obtundation, paresthesia, psychosis, seizure, somnolence, tremor. These symptoms may be marked, particularly in older adults (see PRECAUTIONS ). Skin: Alopecia, erythema multiforme, photosensitive rash, pruritus, rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria. Severe local inflammatory reactions, including tissue necrosis, have occurred following infusion of acyclovir into extravascular tissues. Special Senses: Visual abnormalities. Urogenital: Renal failure, elevated blood urea nitrogen, elevated creatinine (see WARNINGS )."],"contraindications":["CONTRAINDICATIONS Acyclovir Sodium Injection is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir."],"drug_interactions":["Drug Interactions See CLINICAL PHARMACOLOGY, Pharmacokinetics ."],"general_precautions":["General Precipitation of acyclovir crystals in renal tubules can occur if the maximum solubility of free acyclovir (2.5 mg/mL at 37°C in water) is exceeded or if the drug is administered by bolus injection. Ensuing renal tubular damage can produce acute renal failure. Abnormal renal function (decreased creatinine clearance) can occur as a result of acyclovir administration and depends on the state of the patient’s hydration, other treatments, and the rate of drug administration. Concomitant use of other nephrotoxic drugs, pre-existing renal disease, and dehydration make further renal impairment with acyclovir more likely. Administration of acyclovir by intravenous infusion must be accompanied by adequate hydration. When dosage adjustments are required, they should be based on estimated creatinine clearance (see DOSAGE AND ADMINISTRATION ). Approximately 1% of patients receiving intravenous acyclovir have manifested encephalopathic changes characterized by either lethargy, obtundation, tremors, confusion, hallucinations, agitation, seizures, or coma. Acyclovir should be used with caution in those patients who have underlying neurologic abnormalities and those with serious renal, hepatic, or electrolyte abnormalities, or significant hypoxia."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Pharmacokinetics The pharmacokinetics of acyclovir after intravenous administration have been evaluated in adult patients with normal renal function during Phase 1/2 studies after single doses ranging from 0.5 to 15 mg/kg and after multiple doses ranging from 2.5 to 15 mg/kg every 8 hours. Proportionality between dose and plasma levels is seen after single doses or at steady-state after multiple dosing. Average steady-state peak and trough concentrations from 1-hour infusions administered every 8 hours are given in Table 1. Table 1: Acyclovir Peak and Trough Concentrations at Steady-State Dosage Regimen C SS max C SS trough 5 mg/kg q 8 h (n = 8) 9.8 mcg/mL range: 5.5 to 13.8 0.7 mcg/mL range: 0.2 to 1 10 mg/kg q 8 h (n = 7) 22.9 mcg/mL range: 14.1 to 44.1 1.9 mcg/mL range: 0.5 to 2.9 Concentrations achieved in the cerebrospinal fluid are approximately 50% of plasma values. Plasma protein binding is relatively low (9% to 33%) and drug interactions involving binding site displacement are not anticipated. Renal excretion of unchanged drug is the major route of acyclovir elimination accounting for 62% to 91% of the dose. The only major urinary metabolite detected is 9-carboxymethoxymethylguanine accounting for up to 14.1% of the dose in patients with normal renal function. The half-life and total body clearance of acyclovir are dependent on renal function as shown in Table 2. Table 2: Acyclovir Half-life and Total Body Clearance Creatinine Clearance (mL/min/1.73 m 2 ) Half-Life (hr) Total Body Clearance (mL/min/1.73 m 2 ) (mL/min/kg) >80 2.5 327 5.1 50 to 80 3 248 3.9 15 to 50 3.5 190 3.4 0 (Anuric) 19.5 29 0.5 Special Populations Adults With Impaired Renal Function Acyclovir was administered at a dose of 2.5 mg/kg to 6 adult patients with severe renal failure. The peak and trough plasma levels during the 47 hours preceding hemodialysis were 8.5 mcg/mL and 0.7 mcg/mL, respectively. Consult DOSAGE AND ADMINISTRATION section for recommended adjustments in dosing based upon creatinine clearance. Pediatrics Acyclovir pharmacokinetics were determined in 16 pediatric patients with normal renal function ranging in age from 3 months to 16 years at doses of approximately 10 mg/kg and 20 mg/kg every 8 hours (Table 3). Concentrations achieved at these regimens are similar to those in adults receiving 5 mg/kg and 10 mg/kg every 8 hours, respectively (Table 1). Acyclovir pharmacokinetics were determined in 12 patients ranging in age from birth to 3 months at doses of 5 mg/kg, 10 mg/kg, and 15 mg/kg every 8 hours (Table 3). Table 3: Acyclovir Pharmacokinetics in Pediatric Patients (Mean ±SD) Parameter Birth to 3 Months of Age (n = 12) 3 Months to 12 Years of Age (n = 16) CL (mL/min/kg) 4.46 ± 1.61 8.44 ± 2.92 VDSS (L/kg) 1.08 ± 0.35 1.01 ± 0.28 Elimination half-life (hours) 3.8 ± 1.19 2.36 ± 0.97 Geriatrics Acyclovir plasma concentrations are higher in geriatric patients compared to younger adults, in part due to age-related changes in renal function. Dosage reduction may be required in geriatric patients with underlying renal impairment (see PRECAUTIONS, Geriatric Use ). Drug Interactions Coadministration of probenecid with acyclovir has been shown to increase the mean acyclovir half-life and the area under the concentration-time curve. Urinary excretion and renal clearance were correspondingly reduced. Clinical Trials Herpes Simplex Infections in Immunocompromised Patients A multicenter trial of acyclovir at a dose of 250 mg/m 2 every 8 hours (750 mg/m 2 /day) for 7 days was conducted in 98 immunocompromised patients (73 adults and 25 children) with orofacial, esophageal, genital and other localized infections (52 treated with acyclovir and 46 with placebo). Acyclovir decreased virus excretion, reduced pain, and promoted healing of lesions. Initial Episodes of Herpes Genitalis In placebo-controlled trials, 58 patients with initial genital herpes were treated with intravenous acyclovir 5 mg/kg or placebo (27 patients treated with acyclovir and 31 treated with placebo) every 8 hours for 5 days. Acyclovir decreased the duration of viral excretion, new lesion formation, and duration of vesicles, and promoted healing of lesions. Herpes Simplex Encephalitis Sixty-two patients ages 6 months to 79 years with brain biopsy-proven herpes simplex encephalitis were randomized to receive either acyclovir (10 mg/kg every 8 hours) or vidarabine (15 mg/kg/day) for 10 days (28 were treated with acyclovir and 34 with vidarabine). Overall mortality at 12 months for patients treated with acyclovir was 25% compared to 59% for patients treated with vidarabine. The proportion of patients treated with acyclovir functioning normally or with only mild sequelae (e.g., decreased attention span) was 32% compared to 12% of patients treated with vidarabine. Patients less than 30 years of age and those who had the least severe neurologic involvement at time of entry into study had the best outcome with treatment with acyclovir. An additional controlled study performed in Europe demonstrated similar findings. Neonatal Herpes Simplex Virus Infection Two hundred and two infants with neonatal herpes simplex infections were randomized to receive either acyclovir 10 mg/kg every 8 hours (n = 107) or vidarabine 30 mg/kg/day (n = 95) for 10 days. Outcomes are presented in Table 4. Table 4: Mortality at 1 Year * SEM refers to localized infection with disease limited to skin, eye, and/or mouth. † CNS refers to infection of the central nervous system with compatible neurologic and CSF findings. ‡ DISS refers to visceral organ involvement such as hepatitis or pneumonitis with or without CNS involvement. HSV Disease Classification Treatment Group Acyclovir (n = 107) Vidarabine (n = 95) SEM* (n = 85) 0/54 0/31 CNS † (n = 71) 5/35 5/36 DISS ‡ (n = 46) 11/18 14/28 Rates of neurologic sequelae at 1 year were comparable between the treatment groups. Varicella-Zoster Infections in Immunocompromised Patients A multicenter trial of acyclovir at a dose of 500 mg/m 2 every 8 hours for 7 days was conducted in immunocompromised patients with zoster infections (shingles). Ninety-four (94) patients were evaluated (52 patients were treated with acyclovir and 42 with placebo). Acyclovir was superior to placebo as measured by reductions in cutaneous dissemination and visceral dissemination."],"indications_and_usage":["INDICATIONS AND USAGE Herpes Simplex Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immuno-competent patients. Herpes Simplex Encephalitis Acyclovir Sodium Injection is indicated for the treatment of herpes simplex encephalitis. Neonatal Herpes Simplex Virus Infection Acyclovir Sodium Injection is indicated for the treatment of neonatal herpes infections. Varicella-Zoster Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients."],"spl_unclassified_section":["FOR INTRAVENOUS INFUSION ONLY Rx only","VIROLOGY Mechanism of Antiviral Action Acyclovir is a synthetic purine nucleoside analogue with in vitro and in vivo inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2) and varicella-zoster virus (VZV). The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In vitro , acyclovir triphosphate stops replication of herpes viral DNA. This is accomplished in three ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the viral TK. Antiviral Activities The quantitative relationship between the in vitro susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (IC 50 ), vary greatly depending upon a number of factors. Using plaque-reduction assays, the IC 50 against herpes simplex virus isolates ranges from 0.02 to 13.5 mcg/mL for HSV-1 and from 0.01 to 9.9 mcg/mL for HSV-2. The IC 50 for acyclovir against most laboratory strains and clinical isolates of VZV ranges from 0.12 to 10.8 mcg/mL. Acyclovir also demonstrates activity against the Oka vaccine strain of VZV with a mean IC 50 of 1.35 mcg/mL. Drug Resistance Resistance of HSV and VZV to acyclovir can result from qualitative or quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates of HSV and VZV with reduced susceptibility to acyclovir have been recovered from immunocompromised patients, especially with advanced HIV infection. While most of the acyclovir-resistant mutants isolated thus far from such patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have been isolated. TK-negative mutants may cause severe disease in infants and immunocompromised adults. The possibility of viral resistance to acyclovir should be considered in patients who show poor clinical response during therapy."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION CAUTION - RAPID OR BOLUS INTRAVENOUS INJECTION MUST BE AVOIDED (see WARNINGS and PRECAUTIONS ). INTRAMUSCULAR OR SUBCUTANEOUS INJECTION MUST BE AVOIDED (see WARNINGS ). Therapy should be initiated as early as possible following onset of signs and symptoms of herpes infections. A maximum dose equivalent to 20 mg/kg every 8 hours should not be exceeded for any patient. Dosage HERPES SIMPLEX INFECTIONS MUCOSAL AND CUTANEOUS HERPES SIMPLEX (HSV-1 AND HSV-2) INFECTIONS IN IMMUNOCOMPROMISED PATIENTS Adults and Adolescents (12 years of age and older) 5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Pediatrics (Under 12 years of age) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. SEVERE INITIAL CLINICAL EPISODES OF HERPES GENITALIS Adults and Adolescents (12 years of age and older) 5 mg/kg infused at a constant rate over 1 hour, every 8 hours for 5 days. HERPES SIMPLEX ENCEPHALITIS Adults and Adolescents (12 years of age and older) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days. Pediatrics (3 months to 12 years of age) 20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days . Neonatal Herpes Simplex Virus Infections (Birth to 3 months) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 10 days. In neonatal herpes simplex infections, doses of 15 mg/kg or 20 mg/kg (infused at a constant rate over 1 hour every 8 hours) have been used; the safety and efficacy of these doses are not known. VARICELLA-ZOSTER INFECTIONS ZOSTER IN IMMUNOCOMPROMISED PATIENTS Adults and Adolescents (12 years of age and older) 10 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Pediatrics (Under 12 years of age) 20 mg/kg infused at a constant rate over 1 hour, every 8 hours for 7 days. Obese Patients Obese patients should be dosed at the recommended adult dose using Ideal Body Weight. PATIENTS WITH ACUTE OR CHRONIC RENAL IMPAIRMENT Refer to DOSAGE AND ADMINISTRATION section for recommended doses, and adjust the dosing interval as indicated in Table 5. Table 5: Dosage Adjustments for Patients with Renal Impairment Creatinine Clearance (mL/min/1.73 m 2 ) Percent of Recommended Dose Dosing Interval (hours) >50 100% 8 25 to 50 100% 12 10 to 25 100% 24 0 to 10 50% 24 Hemodialysis For patients who require dialysis, the mean plasma half-life of acyclovir during hemodialysis is approximately 5 hours. This results in a 60% decrease in plasma concentrations following a six-hour dialysis period. Therefore, the patient’s dosing schedule should be adjusted so that an additional dose is administered after each dialysis. Peritoneal Dialysis No supplemental dose appears to be necessary after adjustment of the dosing interval. Administration The calculated dose should be further diluted in an appropriate intravenous solution at a volume selected for administration during each 1 hour infusion. Infusion concentrations of approximately 7 mg/mL or lower are recommended. In clinical studies, the average 70 kg adult received between 60 and 150 mL of fluid per dose. Higher concentrations (e.g., 10 mg/mL) may produce phlebitis or inflammation at the injection site upon inadvertent extravasation. Standard, commercially available electrolyte and glucose solutions are suitable for intravenous administration; biologic or colloidal fluids (e.g., blood products, protein solutions, etc.) are not recommended. Once diluted for administration, each dose should be used within 24 hours. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."],"spl_product_data_elements":["Acyclovir Sodium Acyclovir Sodium WATER ACYCLOVIR SODIUM ACYCLOVIR"],"clinical_pharmacology_table":["
Table 1: Acyclovir Peak and Trough Concentrations at Steady-State
Dosage RegimenC SSmax C SStrough
5 mg/kg q 8 h (n = 8) 9.8 mcg/mL range: 5.5 to 13.8 0.7 mcg/mL range: 0.2 to 1
10 mg/kg q 8 h (n = 7) 22.9 mcg/mL range: 14.1 to 44.1 1.9 mcg/mL range: 0.5 to 2.9
","
Table 2: Acyclovir Half-life and Total Body Clearance
Creatinine Clearance (mL/min/1.73 m 2) Half-Life (hr) Total Body Clearance
(mL/min/1.73 m 2) (mL/min/kg)
>80 2.5 327 5.1
50 to 80 3 248 3.9
15 to 50 3.5 190 3.4
0 (Anuric) 19.5 29 0.5
","
Table 3: Acyclovir Pharmacokinetics in Pediatric Patients (Mean ±SD)
Parameter Birth to 3 Months of Age (n = 12) 3 Months to 12 Years of Age (n = 16)
CL (mL/min/kg) 4.46 ± 1.61 8.44 ± 2.92
VDSS (L/kg) 1.08 ± 0.35 1.01 ± 0.28
Elimination half-life (hours) 3.8 ± 1.19 2.36 ± 0.97
","
Table 4: Mortality at 1 Year
* SEM refers to localized infection with disease limited to skin, eye, and/or mouth. †CNS refers to infection of the central nervous system with compatible neurologic and CSF findings. ‡DISS refers to visceral organ involvement such as hepatitis or pneumonitis with or without CNS involvement.
HSV Disease Classification Treatment Group
Acyclovir (n = 107) Vidarabine (n = 95)
SEM* (n = 85) 0/54 0/31
CNS †(n = 71) 5/35 5/36
DISS ‡(n = 46) 11/18 14/28
"],"dosage_and_administration_table":["
Table 5: Dosage Adjustments for Patients with Renal Impairment
Creatinine Clearance (mL/min/1.73 m 2) Percent of Recommended Dose Dosing Interval (hours)
>50 100% 8
25 to 50 100% 12
10 to 25 100% 24
0 to 10 50% 24
"],"package_label_principal_display_panel":["PACKAGE LABEL label"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["Carcinogenesis, Mutagenesis, Impairment of Fertility The data presented below include references to peak steady-state plasma acyclovir concentrations observed in humans treated with 30 mg/kg/day (10 mg/kg every 8 hours, dosing appropriate for treatment of herpes zoster or herpes encephalitis), or 15 mg/kg/day (5 mg/kg every 8 hours, dosing appropriate for treatment of primary genital herpes or herpes simplex infections in immunocompromised patients). Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir at the higher and lower dosing schedules (see CLINICAL PHARMACOLOGY, Pharmacokinetics ). Acyclovir was tested in lifetime bioassays in rats and mice at single daily doses of up to 450 mg/kg administered by gavage. There was no statistically significant difference in the incidence of tumors between treated and control animals, nor did acyclovir shorten the latency of tumors. At 450 mg/kg/day, plasma concentrations in both the mouse and rat bioassay were lower than concentrations in humans. Acyclovir was tested in 16 in vitro and in vivo genetic toxicity assays. Acyclovir was positive in 5 of the assays. Acyclovir did not impair fertility or reproduction in mice (450 mg/kg/day, PO) or in rats (25 mg/kg/day, SC). In the mouse study, plasma levels were the same as human levels, while in the rat study, they were 1 to 2 times human levels. At higher doses (50 mg/kg/day, SC) in rats and rabbits (1 to 2 and 1 to 3 times human levels, respectively) implantation efficacy, but not litter size, was decreased. In a rat peri- and post-natal study at 50 mg/kg/day, SC, there was a statistically significant decrease in group mean numbers of corpora lutea, total implantation sites, and live fetuses. No testicular abnormalities were seen in dogs given 50 mg/kg/day, IV for 1 month (1 to 3 times human levels) or in dogs given 60 mg/kg/day orally for 1 year (the same as human levels). Testicular atrophy and aspermatogenesis were observed in rats and dogs at higher dose levels."]},"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"inflammation or phlebitis at the injection site","drugRate":"9%","_validated":true,"placeboRate":""},{"effect":"transient elevations of serum creatinine or BUN","drugRate":"5% to 10%","_validated":true,"placeboRate":""},{"effect":"nausea and/or vomiting","drugRate":"7%","_validated":true,"placeboRate":""},{"effect":"itching, rash, or hives","drugRate":"2%","_validated":true,"placeboRate":""},{"effect":"elevation of transaminases","drugRate":"1% to 2%","_validated":true,"placeboRate":""}],"contraindications":["Acyclovir Sodium Injection is contraindicated for patients who develop hypersensitivity to acyclovir or valacyclovir."]},"_chembl":{"chemblId":"CHEMBL1200380","moleculeType":"Small molecule","molecularWeight":"247.19"},"patents":[],"_fixedAt":"2026-03-30T14:10:51.640635","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ACYCLOVIR SODIUM","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T07:13:38.555182+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T07:14:44.456506+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T07:13:44.405107+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ACYCLOVIR SODIUM","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T07:13:44.769602+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:13:37.444705+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:14:38.171514+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:13:37.444732+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Human herpesvirus 1 DNA polymerase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:13:46.466683+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200380/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T07:13:46.033875+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"ADVERSE REACTIONS The adverse reactions listed below have been observed in controlled and uncontrolled clinical trials in approximately 700 patients who received acyclovir at approximately 5 mg/kg (250 mg/m 2 ) 3 times daily, and approximately 300 patients who received approximately 10 mg/kg (500 mg/m 2 ) 3 times daily. The most frequent adverse reactions reported during administration of acyclovir were inflammation or phlebitis at the injection site in approximately 9% of the patients, and tran","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:14:01.875783+00:00"},"safety.contraindications":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:14:05.586957+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203701","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T07:13:37.444737+00:00"}},"_dailymed":{"setId":"23a7cf9e-f21b-06c2-e063-6394a90aa623","title":"ACYCLOVIR SODIUM INJECTION, SOLUTION [PROPHARMA DISTRIBUTION]"},"aiSummary":"Acyclovir Sodium is a marketed antiviral drug primarily indicated for treating Herpes Simplex in immunocompromised patients. Its key strength lies in its established use and efficacy in this patient population, supported by a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent approaches expiration.","mechanism":{"modality":"Small Molecule"},"_scrapedAt":"2026-03-28T00:32:47.302Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T07:14:44.457434+00:00","fieldsConflicting":0,"overallConfidence":0.95},"indications":{"approved":[{"id":"acyclovir-sodium-herpes-simplex-in-immunocompro","name":"Herpes Simplex in Immunocompromised Patients","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Immunocompromised patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Immunocompromised patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"acyclovir-sodium-severe-initial-herpes-genitali","name":"Severe Initial Herpes Genitalis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Immuno-competent patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Immuno-competent patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"acyclovir-sodium-herpes-simplex-encephalitis","name":"Herpes Simplex Encephalitis","dosing":null,"approvals":[],"diseaseId":"","eligibility":"All patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"All patients","diagnosticRequired":null,"brandNameForIndication":""},{"id":"acyclovir-sodium-neonatal-herpes-infections","name":"Neonatal Herpes Infections","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Neonates","pivotalTrial":null,"restrictions":[],"patientPopulation":"Neonates","diagnosticRequired":null,"brandNameForIndication":""},{"id":"acyclovir-sodium-varicella-zoster-in-immunocomp","name":"Varicella-Zoster in Immunocompromised Patients","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Immunocompromised patients","pivotalTrial":null,"restrictions":[],"patientPopulation":"Immunocompromised patients","diagnosticRequired":null,"brandNameForIndication":""}]},"_fixedFields":["sideEffects","generics(13)","patents(0)","modality→Small Molecule"],"patentStatus":"Off-patent — no active Orange Book patents","trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT07383649","phase":"PHASE2","title":"Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-03","conditions":"Brain Cancer Metastatic, CMV Viremia","enrollment":28},{"nctId":"NCT05127395","phase":"","title":"Impact of Obesity on Clinical Outcomes in Patients Receiving Acyclovir for HSV Encephalitis\"","status":"COMPLETED","sponsor":"Methodist Health System","startDate":"2021-03-09","conditions":"HSV Encephalitis","enrollment":50},{"nctId":"NCT07332000","phase":"PHASE2","title":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","status":"RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2025-10-30","conditions":"Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)","enrollment":45},{"nctId":"NCT06391918","phase":"PHASE1","title":"Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"GenVivo, Inc.","startDate":"2024-03-04","conditions":"Solid Tumor, Adult","enrollment":37},{"nctId":"NCT06914479","phase":"PHASE1","title":"Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-06-01","conditions":"Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm","enrollment":11},{"nctId":"NCT00492050","phase":"PHASE2","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08-02","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT07448844","phase":"PHASE4","title":"Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir","status":"RECRUITING","sponsor":"Riphah International University","startDate":"2026-02-20","conditions":"Viral Wart, Plantar Wart, Common Warts (Verruca Vulgaris)","enrollment":40},{"nctId":"NCT03586284","phase":"PHASE2, PHASE3","title":"Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2020-03-15","conditions":"Cytomegalovirus Anterior Uveitis","enrollment":51},{"nctId":"NCT07341386","phase":"PHASE4","title":"Prevention of Recurrence of Herpes Simplex in Autoimmune Rheumatic Diseases","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-04-01","conditions":"Autoimmune Rheumatic Diseases, Recurrent Herpes Simplex, Prevention","enrollment":62},{"nctId":"NCT07346144","phase":"PHASE1, PHASE2","title":"Study of an AAV Mediated Dual-Payload Gene Therapy in Patients With High Grade Glioma","status":"NOT_YET_RECRUITING","sponsor":"Trogenix ltd","startDate":"2026-03","conditions":"Glioblastoma (GBM), High Grade Gliomas, Recurrent Glioblastoma","enrollment":68},{"nctId":"NCT05536349","phase":"PHASE2","title":"Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-12-20","conditions":"Leukemia","enrollment":60},{"nctId":"NCT05468619","phase":"PHASE1","title":"Neonatal Phase 1 Valacyclovir Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-08-07","conditions":"Herpes Simplex","enrollment":17},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":"Mild Cognitive Impairment, Dementia, Mild","enrollment":73},{"nctId":"NCT07235683","phase":"PHASE4","title":"Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-12-24","conditions":"CMV, Lung Transplant Recipient","enrollment":40},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT07379203","phase":"PHASE2","title":"ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse","status":"NOT_YET_RECRUITING","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2026-02-01","conditions":"Cytomegalovirus (CMV) Infection","enrollment":130},{"nctId":"NCT01199562","phase":"","title":"Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2010-12","conditions":"Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia","enrollment":153},{"nctId":"NCT07363031","phase":"PHASE2","title":"Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy","status":"ENROLLING_BY_INVITATION","sponsor":"Instituto Oncoclinicas","startDate":"2022-09-05","conditions":"Oral Mucositis, Head and Neck Cancer (H&N), Radiotherapy Side Effects","enrollment":84},{"nctId":"NCT07349680","phase":"PHASE3","title":"Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia","status":"COMPLETED","sponsor":"Assiut University","startDate":"2023-03-15","conditions":"Postherpetic Neuralgia","enrollment":100},{"nctId":"NCT03178149","phase":"PHASE1","title":"A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration","status":"RECRUITING","sponsor":"Astellas Institute for Regenerative Medicine","startDate":"2018-07-13","conditions":"Age-Related Macular Degeneration","enrollment":42},{"nctId":"NCT06558838","phase":"PHASE2","title":"Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions","status":"COMPLETED","sponsor":"University of Utah","startDate":"2024-08-19","conditions":"Herpes Simplex Oral","enrollment":40},{"nctId":"NCT06334497","phase":"PHASE3","title":"Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-08-14","conditions":"Cytomegalovirus Infection","enrollment":80},{"nctId":"NCT05589688","phase":"PHASE1","title":"Individualization of Dosage Regimens in Obese Patients: Application to Acyclovir","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-04-09","conditions":"Obesity","enrollment":20},{"nctId":"NCT04116411","phase":"PHASE2","title":"A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cecilia Soderberg-Naucler","startDate":"2019-09-04","conditions":"Glioblastoma Multiforme","enrollment":220},{"nctId":"NCT07294547","phase":"NA","title":"Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-11-27","conditions":"Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis","enrollment":80},{"nctId":"NCT04706507","phase":"PHASE3","title":"Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-06-29","conditions":"Acute Respiratory Failure","enrollment":205},{"nctId":"NCT07266467","phase":"PHASE4","title":"Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients","status":"RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2025-05-13","conditions":"Kidney Transplant","enrollment":290},{"nctId":"NCT03073967","phase":"PHASE3","title":"Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects","status":"COMPLETED","sponsor":"AiCuris Anti-infective Cures AG","startDate":"2017-05-08","conditions":"HSV Infection","enrollment":158},{"nctId":"NCT04710030","phase":"PHASE2","title":"Valacyclovir for Mild Cognitive Impairment","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2021-02-01","conditions":"Mild Cognitive Impairment, Herpes Simplex 1, Herpes Simplex 2","enrollment":50},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":"Multiple Sclerosis","enrollment":16},{"nctId":"NCT06134492","phase":"PHASE3","title":"Acyclovir in Ventilated Patients With Pneumonia and HSV-1 in BAL","status":"RECRUITING","sponsor":"Jena University Hospital","startDate":"2024-02-20","conditions":"Pneumonia, Viral, Ventilator Associated Pneumonia, Community-acquired Pneumonia","enrollment":616},{"nctId":"NCT06853184","phase":"PHASE2","title":"Study Evaluating the Efficacy and Safety of Artesunate","status":"RECRUITING","sponsor":"Amivas Inc.","startDate":"2025-08-01","conditions":"CMV Infection","enrollment":90},{"nctId":"NCT06034925","phase":"PHASE4","title":"Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":"Transplant Complication, CMV","enrollment":70},{"nctId":"NCT06798909","phase":"PHASE3","title":"Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-07-22","conditions":"Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases","enrollment":360},{"nctId":"NCT05452928","phase":"PHASE4","title":"Aciclovir Versus Placebo for HSV-2 Meningitis","status":"NOT_YET_RECRUITING","sponsor":"Jacob Bodilsen","startDate":"2026-06-01","conditions":"Herpes Simplex 2, Meningitis, Viral","enrollment":150},{"nctId":"NCT07196670","phase":"PHASE4","title":"Intralesional Vitamin D Versus Intralesional Acyclovir in Plantar Warts","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-09","conditions":"Plantar Warts Treatment","enrollment":60},{"nctId":"NCT03282916","phase":"PHASE2","title":"Anti-viral Therapy in Alzheimer's Disease","status":"COMPLETED","sponsor":"Columbia University","startDate":"2018-02-12","conditions":"Alzheimer Disease, Herpes Simplex 1, Herpes Simplex 2","enrollment":120},{"nctId":"NCT07079735","phase":"PHASE2, PHASE3","title":"Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant","status":"RECRUITING","sponsor":"Columbia University","startDate":"2025-09-12","conditions":"CMV Viremia, Heart Transplant Infection, Heart Transplant Failure and Rejection","enrollment":150},{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT06102525","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma","status":"RECRUITING","sponsor":"Rznomics, Inc.","startDate":"2024-10-08","conditions":"Glioblastoma","enrollment":43},{"nctId":"NCT05098938","phase":"PHASE3","title":"A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-11-23","conditions":"Recurrent Herpes Labialis","enrollment":2020},{"nctId":"NCT07138989","phase":"PHASE2","title":"EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-19","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":10},{"nctId":"NCT04495153","phase":"PHASE2","title":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2020-10-13","conditions":"Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT02768363","phase":"PHASE2","title":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2016-05","conditions":"Prostate Cancer","enrollment":187},{"nctId":"NCT01436968","phase":"PHASE3","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":711},{"nctId":"NCT05708755","phase":"PHASE2","title":"CMV Immunity Monitoring in Lung Transplant Recipients","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-09-13","conditions":"Lung Transplant; Complications","enrollment":50},{"nctId":"NCT05011058","phase":"PHASE2","title":"An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas","status":"TERMINATED","sponsor":"Viracta Therapeutics, Inc.","startDate":"2021-05-28","conditions":"Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma","enrollment":102},{"nctId":"NCT03131037","phase":"PHASE1","title":"Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2017-05-04","conditions":"Lung Cancer","enrollment":12},{"nctId":"NCT06436534","phase":"NA","title":"Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-05-24","conditions":"Rhinitis, Allergic","enrollment":50},{"nctId":"NCT05041426","phase":"PHASE2","title":"Letermovir for CMV Prevention After Lung Transplantation","status":"COMPLETED","sponsor":"Fernanda P Silveira, MD, MS","startDate":"2021-12-06","conditions":"Lung Transplant, CMV","enrollment":16},{"nctId":"NCT04448392","phase":"PHASE1","title":"Valacyclovir in Neonatal Herpes Simplex Virus Disease","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-07-01","conditions":"Neonatal Herpes Simplex Infection","enrollment":7},{"nctId":"NCT07014397","phase":"NA","title":"Effect of Valaciclovir on Inter-Appointment Pain in Endodontic Treatment of Necrotic Teeth","status":"COMPLETED","sponsor":"Tehran University of Medical Sciences","startDate":"2024-11-01","conditions":"Symptomatic Apical Periodontitis","enrollment":38},{"nctId":"NCT05198570","phase":"","title":"Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients","status":"RECRUITING","sponsor":"University of Pisa","startDate":"2021-09-15","conditions":"Herpesviridae Infections, Herpes Simplex 1, Varicella Zoster Virus Infection","enrollment":200},{"nctId":"NCT05266040","phase":"PHASE2","title":"Valacyclovir in Pain Management of Acute Apical Abscesses","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2023-10-25","conditions":"Acute Apical Abscess, Pain, Acute","enrollment":60},{"nctId":"NCT06474416","phase":"PHASE1","title":"A Study of the Safety, Tolerability and Prelinminary Efficacy of BD111 in Herpes Simplex Virus Type I Stromal Keratitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai BDgene Co., Ltd.","startDate":"2023-09-04","conditions":"Herpes Simplex Virus Type I Stromal Keratitis","enrollment":16},{"nctId":"NCT05550194","phase":"PHASE4","title":"VZV in the Enteric Nervous System: Pathogenesis and Consequences","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-03-27","conditions":"Achalasia","enrollment":40},{"nctId":"NCT06971913","phase":"PHASE2","title":"Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV Viremia","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-05-20","conditions":"SLE (Systemic Lupus), CMV","enrollment":100},{"nctId":"NCT05564598","phase":"PHASE2","title":"CMV CTLs in Neonates With CMV Infection","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2023-07-01","conditions":"Congenital Cytomegaloviral (CMV) Disease","enrollment":23},{"nctId":"NCT06307444","phase":"NA","title":"Ultrasound-Guided Erectro Spinae Plane Block Versus Stellate Ganglion Block for Patients With Upper Limb Acute Herpes Zoster Pain.","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-03-20","conditions":"Acute Herpes Zoster Pain Managment","enrollment":93},{"nctId":"NCT03397706","phase":"PHASE1, PHASE2","title":"Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies","status":"COMPLETED","sponsor":"Viracta Therapeutics, Inc.","startDate":"2018-03-29","conditions":"Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders","enrollment":64},{"nctId":"NCT05166577","phase":"PHASE1","title":"Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC","status":"TERMINATED","sponsor":"Viracta Therapeutics, Inc.","startDate":"2021-10-08","conditions":"Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma","enrollment":26},{"nctId":"NCT03134196","phase":"PHASE4","title":"Zoster Eye Disease Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-08-23","conditions":"Herpes Zoster Ophthalmicus","enrollment":527},{"nctId":"NCT04724447","phase":"PHASE1, PHASE2","title":"ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION","status":"RECRUITING","sponsor":"Laureate Institute for Brain Research, Inc.","startDate":"2021-11-23","conditions":"Major Depressive Disorder","enrollment":24},{"nctId":"NCT02879630","phase":"","title":"Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity","status":"RECRUITING","sponsor":"West Virginia University","startDate":"2016-08","conditions":"Obesity","enrollment":20},{"nctId":"NCT05789615","phase":"","title":"Letermovir Prophylaxis for CMV Infection in Haplo-HSCT Recipients: Single-center Data in China","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-04-01","conditions":"CMV Infection, Hematopoietic Stem Cell Transplantation","enrollment":200},{"nctId":"NCT03576612","phase":"PHASE1","title":"GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2018-02-27","conditions":"Glioma, Malignant","enrollment":41},{"nctId":"NCT04188327","phase":"NA","title":"Stellate Ganglion Block in Herpes Zoster","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-05-01","conditions":"Pain, Neuropathic","enrollment":208},{"nctId":"NCT06302140","phase":"PHASE1","title":"A Mass Balance Study of [14C]-Nanatinostat and Relative Bioavailability Study of Nanatinostat in Patients With Advanced Cancers","status":"TERMINATED","sponsor":"Viracta Therapeutics, Inc.","startDate":"2024-02-28","conditions":"Advanced Cancer","enrollment":8},{"nctId":"NCT06757907","phase":"NA","title":"Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-10-01","conditions":"Herpetic Keratitis","enrollment":20},{"nctId":"NCT06693362","phase":"PHASE1","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-20","conditions":"Severe Viral Pneumonia(Not Include COVID-19)","enrollment":60},{"nctId":"NCT05238220","phase":"","title":"Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Piedmont Healthcare","startDate":"2021-01-04","conditions":"Kidney Transplant; Complications","enrollment":37},{"nctId":"NCT01649869","phase":"PHASE2","title":"Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-02-24","conditions":"Cytomegalovirus Infection","enrollment":54},{"nctId":"NCT03004183","phase":"PHASE2","title":"SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2017-07-01","conditions":"Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer","enrollment":57},{"nctId":"NCT00227370","phase":"PHASE3","title":"Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation","status":"COMPLETED","sponsor":"Duke University","startDate":"2003-07","conditions":"Cytomegalovirus Infections","enrollment":136},{"nctId":"NCT05446571","phase":"PHASE3","title":"Prenatal Treatment of Congenital Cytomegalovirus Infection with Letermovir Versus Valaciclovir","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-20","conditions":"Pregnant Women, CMV Infected Fetuses","enrollment":46},{"nctId":"NCT01149460","phase":"PHASE1","title":"Valacyclovir 1000 mg Tablet Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-09","conditions":"Healthy","enrollment":36},{"nctId":"NCT05720715","phase":"PHASE4","title":"Clinical Outcomes of Cyclosporine Eye Drops in Management of Herpetic Keratitis","status":"COMPLETED","sponsor":"Farwaniya Hospital","startDate":"2022-01-01","conditions":"Outcomes of Cyclosporine Eye Drops in Herpetic Keratitis","enrollment":30},{"nctId":"NCT04640571","phase":"PHASE4","title":"Impact of Metformin and Polysorbate 80 on Drug Absorption and Disposition","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2021-04-01","conditions":"Bile Salt Export Pump (BSEP) Transporter, Polysorbate 80","enrollment":18},{"nctId":"NCT05578820","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics Investigation of Stimotimagene Copolymerplasmid","status":"COMPLETED","sponsor":"Gene Surgery LLC","startDate":"2022-01-01","conditions":"Sarcoma, Melanoma, Squamous Cell Carcinoma of Head and Neck","enrollment":21},{"nctId":"NCT06476080","phase":"NA","title":"Ultrasound Guided Serratus Anterior Versus Erector Spinae Block in Pain Alleviation in Acute Herpes Zoster","status":"NOT_YET_RECRUITING","sponsor":"Minia University","startDate":"2024-07-05","conditions":"Acute Herpes Zoster Neuropathy","enrollment":120},{"nctId":"NCT02073097","phase":"PHASE1, PHASE2","title":"Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2015-01-28","conditions":"Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT06380647","phase":"NA","title":"Comparison of Prophylactic Acyclovir and Placebo in Prevention of Eczema Herpeticum in Pediatric Burns","status":"COMPLETED","sponsor":"King Edward Medical University","startDate":"2019-10-01","conditions":"Herpes Virus Infection","enrollment":64},{"nctId":"NCT00650494","phase":"PHASE1","title":"Fed Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-08","conditions":"Healthy","enrollment":66},{"nctId":"NCT00649974","phase":"PHASE1","title":"Fasting Study of Valacyclovir Hydrochloride Tablets 1000 mg and Valtrex® Tablets 1000 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-05","conditions":"Healthy","enrollment":28},{"nctId":"NCT00649870","phase":"PHASE1","title":"Food Study of Valacyclovir Hydrochloride Tablets 1000 mg to Valtrex® Tablets 1000 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2005-05","conditions":"Healthy","enrollment":26},{"nctId":"NCT04064697","phase":"PHASE3","title":"Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring Vedolizumab Therapy","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2021-04-22","conditions":"Ulcerative Colitis, Unspecified","enrollment":6},{"nctId":"NCT06344195","phase":"PHASE4","title":"Valacyclovir Monotherapy in Pain Management of Acute Periapical Abscesses After Emergency Chamber Opening","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2024-03-27","conditions":"Acute Apical Abscess","enrollment":82},{"nctId":"NCT00589875","phase":"PHASE2","title":"Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2007-03","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":52},{"nctId":"NCT06341686","phase":"PHASE3","title":"Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection","status":"NOT_YET_RECRUITING","sponsor":"Hospital do Rim e Hipertensão","startDate":"2024-05-05","conditions":"CMV Infection","enrollment":100},{"nctId":"NCT06261684","phase":"PHASE2, PHASE3","title":"Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial.","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2023-10-01","conditions":"Plantar Wart","enrollment":92},{"nctId":"NCT06228430","phase":"PHASE1","title":"The Bioequivalence Study of Acyclovir 800 mg Tablet in Healthy Thai Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"International Bio service","startDate":"2024-02-12","conditions":"Healthy Volunteer","enrollment":40},{"nctId":"NCT06217406","phase":"NA","title":"Preemptive Treatment With Acyclovir in Intubated and Mechanically Ventilated Patients With Herpes (PTH2)","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-01","conditions":"Invasive Mechanical Ventilation, HSV Throat Reactivation","enrollment":246},{"nctId":"NCT02446093","phase":"PHASE2","title":"Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2015-10","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":54},{"nctId":"NCT05492591","phase":"PHASE2","title":"A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster","status":"COMPLETED","sponsor":"Shanghai Institute Of Biological Products","startDate":"2022-10-11","conditions":"Herpes Zoster","enrollment":50},{"nctId":"NCT04037475","phase":"NA","title":"Treatment of Herpes Labialis by Photodynamic Therapy","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2020-01-01","conditions":"Photodynamic Therapy, Herpes Simplex, Labial","enrollment":24},{"nctId":"NCT04478474","phase":"","title":"Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2020-09-15","conditions":"Cytomegalovirus Infections","enrollment":100},{"nctId":"NCT02831933","phase":"PHASE2","title":"Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma","status":"TERMINATED","sponsor":"Eric Bernicker, MD","startDate":"2017-02-15","conditions":"Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma","enrollment":11},{"nctId":"NCT03699254","phase":"PHASE3","title":"Clinical Trial of Efficacy and Safety of the Combination of Reduced Duration Prophylaxis Followed by Immuno-guided Prophylaxis in Lung Transplant Recipients.","status":"COMPLETED","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2019-04-05","conditions":"Transplantation Infection, Cytomegalovirus Infections","enrollment":150},{"nctId":"NCT01997190","phase":"PHASE1","title":"Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2013-10","conditions":"Malignant Pleural Effusion, Lung Cancer, Mesothelioma","enrollment":19}],"_emaApprovals":[],"_faersSignals":[],"administration":{"route":"Intravenous"},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL1200380"},"_approvalHistory":[{"date":"20131011","type":"ORIG","sponsor":"EUGIA PHARMA","applicationNumber":"ANDA203701"}],"publicationCount":31,"genericManufacturers":13,"_genericFilersChecked":true,"genericManufacturerList":["Abbvie","Apothecon","Chartwell Injectable","Dr Reddys","Eugia Pharma","Eurohlth Intl Sarl","Fresenius Kabi Usa","Hikma","Hospira","Pharmobedient","Slate Run Pharma","Teva Parenteral","Zydus Pharms"],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"approved","brandName":"ACYCLOVIR SODIUM","genericName":"ACYCLOVIR SODIUM","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1982","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T07:14:44.457434+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}